Physician profile
Mark C Tsai
NPI 1225033111
$13,027.61
in general payments reported to CMS, 2019-2025
36 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $1,413 · 2021: $2,620 · 2022: $2,080 · 2023: $1,411 · 2024: $1,842 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,258 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,258.24 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,123.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,527.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,453.54 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,092.12 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $823.54 | 2019-2024 | Afrezza |
| Madrigal Pharmaceuticals | $657.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $520.29 | 2021-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $471.63 | 2022-2025 | |
| Pfizer INC. | $441.02 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $428.38 | 2020-2024 | Hetlioz, Fanapt |
| Dexcom, INC. | $420.06 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.19 | 2019-2023 | Jardiance |
| Amgen INC. | $379.35 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Glaxosmithkline, LLC. | $331.96 | 2020-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $296.22 | 2019-2024 | Capvaxive, Pneumovax 23, Gardasil 9 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.